TrialNature communications2025

Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS).

Romualdo Barroso-Sousa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.